Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
Angela L. Liang, Payam Katebi Kashi, Mark Hopkins and 4 more
Gynecologic Oncology Reports · 2021
doi:10.1016/j.gore.2021.100877 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
•A subset of patients with uterine carcinosarcoma will have ER/PR positive disease.•Hormone receptor expression may serve as a therapeutic target in high-grade endometrial tumors.•Hormonal therapy and SBRT may have benefit in the management of recurrent uterine carcinosarcoma.
Abstract licence: CC BY-NC-ND
References21
21 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.